For example, NK cells serve as an important effector population in chronic lymphocytic leukemia (CLL) patients who mediate antibody-dependent cell-mediated cytotoxicity through FcγRIIIa (CD16a) receptor engagement by the FDA-approved anti-CD20 antibodies (rituximab, obinutuzumab, and ofatumumab), anti-CD52 antibody alemtuzumab, and other promising anti-CD19 antibodies (MEDI-551 and XmAb5574) that are currently in clinical trials (16). The gene discussed is FCGR3A; the disease is B-cell chronic lymphocytic leukemia.